ArticleJAC-antimicrobial resistance2026
Recurrent infections caused by ESBL-producing enterobacterales with or without subsequent development of distinct carbapenem-resistant phenotypes: differential driving factors and impact on outcome.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to identify factors contributing to distinct carbapenem-resistant phenotypes and associated healthcare utilization and outcomes in patients with ESBL-producing Methods: A retrospective longitudinal evaluation of patients with repeated isolation of clonally related EC or KP during separate encounters. Patients were grouped by carbapenem susceptibility trajectory: (1) ESBL-ESBL; (2) ESBL-cHR; and (3) ESBL-CR. Groups were compared for host and microbial characteristics, antimicrobial exposure, and outcomes. Results: 30 patients (14 ESBL-ESBL, 9 ESBL-cHR, and 7 ESBL-CR) contributed 111 encounters involving 55 EC and 56 KP. Carbapenem-resistant groups demonstrated significantly greater need for feeding tubes and central venous catheters, particularly after resistance evolved from ESBL. The ESBL-CR group was primarily involved by KP from wound and respiratory sites, whereas the ESBL-ESBL and ESBL-cHR groups were predominantly EC from urine and blood. Compared to the ESBL-ESBL group, the ESBL-CR group had the most healthcare visits, whereas the ESBL-cHR group had the longest intervals between visits. Following resistance evolution, hospitalization duration increased by 3 and 1 day, respectively, for ESBL-CR and ESBL-cHR groups ( Conclusions: Evolution from ESBL to carbapenem-resistant phenotypes appeared organism-specific, as EC showed patterns consistent with cHR emergence over longer intervals and lower carbapenem exposure, whereas KP more often progressed to CR from non-urinary sources with greater healthcare utilization. If confirmed in a larger cohort, these observations may inform organism-specific stewardship strategies, enhanced diagnostics for ESBL-cHR, and further investigation into non-antibiotic mechanisms driving heteroresistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.